Follow real-time updates on Union Budget 2023Catch exclusive videos on Union Budget 2023 from CNBC-TV18
International data available on booster doses of AstraZeneca and Covishield suggests a three- to four-fold increase in antibody levels after their administration, Minister of State for Health Bharati Pravin Pawar told the Rajya Sabha on Tuesday.
An ICMR study to examine the effect of Covaxin's booster dose has shown an increase in the levels of antibodies against SARS-CoV-2, Minister of State for Health Bharati Pravin Pawar told the Rajya Sabha on Tuesday. International data available on booster doses of AstraZeneca and Covishield suggests a three- to four-fold increase in antibody levels after their administration, Pawar said in a written reply.
Recommended ArticlesView All
World Cancer Day 2023: Early detection is crucial for reducing the global burden
Feb 4, 2023 IST5 Min(s) Read
World Cancer Day 2023: A way forward to better management of cancer this year!
Feb 4, 2023 IST6 Min(s) Read
Pakistan economy at alarming level as foreign reserves drop to $3.1 billion from $16.6 billion in a year
Feb 3, 2023 IST3 Min(s) Read
FM Nirmala Sitharaman speaks on inflation, taxes, GDP and more. Read the full interview here
Feb 3, 2023 IST37 Min(s) Read
"A study has been conducted by Indian Council of Medical Research (ICMR) to examine the effect of booster dose of Covaxin which shows increase in the levels of neutralising antibodies against SARS-CoV-2 after the booster dose," Pawar stated.
As per the recommendation of the National Technical Advisory Group on Immunization (NTAGI), precaution dose is administered to healthcare workers, frontline workers, and people aged 60 years and above since January 10,2022, she said.
As on March 24, 2022, 2.21 crore precaution doses against COVID-19 have been administered.
First Published: Mar 29, 2022 4:07 PM IST